Search research articles
Contact Us
Filters
Showing results (331-340 of 682) with videos related to
Page
of 69
Sort By:
Journal of the National Cancer Institute
|
September 15, 1993
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer
M F Kohler, J R Marks, R W Wiseman, et al.
Human Pathology
|
November 1, 1996
Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma
F A van den Brule, C Buicu, A Berchuck, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 1, 1993
Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma
K A Leopold, J R Oleson, D Clarke-Pearson, et al.
Gynecologic Oncology
|
June 6, 2021
Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada
Gillian E Hanley, Paramdeep Kaur, Andrew Berchuck, et al.
Gynecologic Oncology
|
December 17, 2009
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype
Jason C Barnett, Sarah M Bean, Regina S Whitaker, et al.
Gynecologic Oncology
|
March 19, 2019
A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery
Catherine H Watson, Micael Lopez-Acevedo, Gloria Broadwater, et al.
International Journal of Cancer
|
July 31, 2009
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer
Paula S Lee, Vanessa S Teaberry, Amy E Bland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 28, 2012
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer
Angeles Alvarez Secord, Deanna K Teoh, William T Barry, et al.
Virchows Archiv : an International Journal of Pathology
|
July 12, 2002
Cell proliferation and apoptosis in human uterine leiomyomas and myometria
Darlene Dixon, Gordon P Flake, Alicia B Moore, et al.
Gynecologic Oncology
|
December 31, 2002
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer
Laura J Havrilesky, Angeles A Alvarez, Robyn A Sayer, et al.
Page
of 69
Search research articles
Search
Showing results (331-340 of 682) with videos related to
Sort By:
Page
of 69
Journal of the National Cancer Institute
|
September 15, 1993
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer
M F Kohler, J R Marks, R W Wiseman, et al.
Human Pathology
|
November 1, 1996
Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma
F A van den Brule, C Buicu, A Berchuck, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 1, 1993
Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma
K A Leopold, J R Oleson, D Clarke-Pearson, et al.
Gynecologic Oncology
|
June 6, 2021
Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada
Gillian E Hanley, Paramdeep Kaur, Andrew Berchuck, et al.
Gynecologic Oncology
|
December 17, 2009
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype
Jason C Barnett, Sarah M Bean, Regina S Whitaker, et al.
Gynecologic Oncology
|
March 19, 2019
A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery
Catherine H Watson, Micael Lopez-Acevedo, Gloria Broadwater, et al.
International Journal of Cancer
|
July 31, 2009
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer
Paula S Lee, Vanessa S Teaberry, Amy E Bland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 28, 2012
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer
Angeles Alvarez Secord, Deanna K Teoh, William T Barry, et al.
Virchows Archiv : an International Journal of Pathology
|
July 12, 2002
Cell proliferation and apoptosis in human uterine leiomyomas and myometria
Darlene Dixon, Gordon P Flake, Alicia B Moore, et al.
Gynecologic Oncology
|
December 31, 2002
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer
Laura J Havrilesky, Angeles A Alvarez, Robyn A Sayer, et al.
Page
of 69